Clin. eff. & PROs in mod.-sev. AD pts treated w/ oral systemics: 12-wk interim results from AD-REAL focusing on pts w/ BSA 7 ('itch dominant')
Por:
Augustin, M, Serra-Baldrich, E, Seneschal, J, Elrayes, M, Otero-Asman, JR, Berkery, E, Fakouri, W, Bewley, A, Garcia-Latasa, J, Pinter, A, Schlöbe, A
Publicada:
1 abr 2025
Resumen:
Filiaciones:
Augustin, M:
Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
Serra-Baldrich, E:
Univ Autonoma Barcelona, Hosp St Pau, Dept Dermatol, Cutaneous Allergy Unit, Barcelona, Spain
Seneschal, J:
Univ Bordeaux, Natl Reference Ctr Rare Skin Disorders, Dept Dermatol, Bordeaux, France
Elrayes, M:
Eli Lilly & Co, Indianapolis, IN USA
Otero-Asman, JR:
Eli Lilly & Co, Indianapolis, IN USA
Berkery, E:
Eli Lilly & Co, Indianapolis, IN USA
Fakouri, W:
Eli Lilly & Co, Indianapolis, IN USA
Bewley, A:
Royal London Hosp, Dept Dermatol, London, England
Garcia-Latasa, J:
Ctr Especial Med Grande Covian, Zaragoza, Spain
Pinter, A:
Univ Hosp Frankfurt, Venereol & Allergol, Frankfurt, Germany
Schlöbe, A:
Lilly Deutschland, Bad Homburg, Germany
|